Mach7 Technologies Secures A$5M Licence Agreement Amendment

Mach7 Technologies ( (AU:M7T) ) has issued an update.

Mach7 Technologies has signed a 5-year licence agreement amendment worth A$5 million with a major US-based radiology marketplace, extending the previous subscription by three years and increasing the total contract value by A$3 million. This agreement underscores Mach7’s commitment to building long-term customer relationships and the effectiveness of its ‘land and expand’ strategy, highlighting the company’s strong value proposition and the significant return on investment its products offer.

The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.

More about Mach7 Technologies

Mach7 Technologies is a medical imaging technology provider that develops innovative data management and image viewing solutions for healthcare organizations. Its core offering is the Mach7 Enterprise Imaging Solution, which includes a Vendor Neutral Archive, eUnity Enterprise Diagnostic Viewer, and Diagnostic Workflow Applications. Mach7 serves a global network of customers, including expansive IDNs, National Health Systems, and private radiology practices.

Average Trading Volume: 250,015

Technical Sentiment Signal: Sell

Current Market Cap: A$75.99M

For a thorough assessment of M7T stock, go to TipRanks’ Stock Analysis page.